key: cord-0979511-c3wj78xm
authors: Newell, Krista L.; Waickman, Adam T.
title: Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infection
date: 2022-05-24
journal: Curr Opin Immunol
DOI: 10.1016/j.coi.2022.102228
sha: 3ff8bed2415183a5ecb9034f0f9a3d11aace08d1
doc_id: 979511
cord_uid: c3wj78xm

SARS-CoV-2 infection is known to result in a range of symptoms with varying degrees of acute phase severity. In a subset of individuals an equally diverse collection of long-term sequelae has been reported after convalescence. As survivorship and therefore the number of individuals with “long-COVID” continues to grow, an understanding of the prevalence, origins, and mechanisms of post-acute sequelae manifestation is critically needed. Here, we will explore proposed roles of the anti-SARS-CoV-2 immune response in the onset, severity, and persistence of SARS-CoV-2 post-acute sequelae. We discuss the potential roles of persistent virus and autoantigens in this syndrome, as well as the contributions of unresolved inflammation and tissue injury. Furthermore, we highlight recent evidence demonstrating the potential benefits of vaccination and immunity in the resolution of post-acute symptoms.

stating that PASC significantly impacts their ability to perform basic daily tasks. Both the frequency and overall number of convalescent COVID-19 patients that experience post-acute sequelae of infection make it a significant public health concern.

Despite the prevalence and growing awareness of PASC the physiological mechanisms underpinning the phenomena remain poorly defined. This is in part due to the diverse array of symptoms associated with PASC, the fundamental complexities of COVID-19 pathogenesis, and the lack of a concrete and consistently-applied clinical definition of PASC. Only recently have large-scale studies started to shed light on the full clinical burden of PASC and on the risk factors associated with PASC severity and persistence. Both premorbid risk factorssuch as hypertension, obesity and immunosuppressionas well as the duration and severity of acute COVID-19 illness appear to correlate with the severity and persistence of PASC [3, 4, [6] [7] [8] [9] . However, a common theme is the presence of persistent inflammation and immune activation beyond the acute infectious insult. Here we will explore the association between persistent inflammation and PASC, as well as several potential mechanisms for the induction and maintenance of dysregulated antigen-specific immune responses following the resolution of acute SARS-CoV-2 infection (Figure 1 ).

There is mounting evidence that PASC is accompanied by dysregulated and persistent multi-organ inflammation [10] [11] [12] [13] . Elevated serum levels of C-reactive protein, TNFα, IFNγ, and IL-6 have been observed in convalescent COVID-19 patients who progressed to develop PASC, with the quantity of these inflammatory markers correlating with the number of patientsupplied PASC symptoms [9, 10] . Notably, Phetsouphanh et al. have described persistent J o u r n a l P r e -p r o o f immunological dysfunction in individuals at 8 months after non-severe SARS- CoV-2 infection   characterized by highly activated innate immune signatures and higher expression of both type   I and III IFN, as well as CXCL9, CXCL10, IL-8 and sTIM-3 [14] . In individuals with PASC, this unresolved infection-attendant inflammation is postulated to drive tissue damage, endothelial dysregulation, hypoxia-induced injury, and activation of pathogenic effector lymphocyte subsets [15] [16] [17] .

Unchecked inflammation and dysregulated adaptive immune responses have been associated with long-term sequelae following the resolution of many other viral pathogens including Ebola, Lassa, Chikungunya, and influenza viruses [18] [19] [20] . For SARS-CoV-2, persistent immune activation has been shown to result in endothelial dysfunction in convalescent COVID-19 patients [16] . This study additionally identified circulating activated endothelial cells following the resolution of acute infection, postulating that this indicator of vascular injury was a consequence of proinflammatory cytokine production by activated cytotoxic CD8 + T cells. Notably, they also observed higher frequencies of effector T cells in subjects with pre-existing cardiovascular conditions and other comorbidities associated with was not accompanied by cytopathic tissue damage or marked inflammation in these individuals [28] . Therefore, while SARS-CoV-2 genetic material may persist long after the initial J o u r n a l P r e -p r o o f acute infection, it is unlikely that this represents a truly persistent or latent viral infection. A provocative hypothesis proposed by recent reports is the possibility that SARS-CoV-2 is capable of partial genomic integration, resulting in a somatic source of persistent antigen and sub-genomic RNA [30] . This speculation has been intensely disputed [31] [32] [33] , and will demand further examination as a potential source of persistent viral antigen that may be capable of driving protracted inflammation. infection symptoms is associated with the persistence, but not magnitude, of antigen-specific adaptive immunes responses [36, 37] . It is therefore plausible that clearance of persistent antigen or a return to immunological baseline as a consequence of vaccination contributes to the resolution of PASC.

While there is evidence suggesting the persistence of SARS-CoV-2 genomic material beyond the acute infection phase, persistent immune activation directed towards SARS-CoV-2

is not dependent on prolonged viral replication or de novo antigen production. Multiple immunological mechanisms exist to retain antigen for the purpose of maturing immunological J o u r n a l P r e -p r o o f memory after the resolution of an acute infectious insult [38, 39] . Most notably, follicular dendritic cells can retain protein antigens in germinal centers (GCs) within lymph nodes or spleen for months after initial antigen production. Indeed, the long-term retention of SARS-CoV-2 antigen within GCs has been suggested to drive clonal and mutational maturation of memory B cells isolated from convalescent COVID-19 patients [29, 40] . A separate study identified reduced total IgM or IgG3 levels as a predictor of PASC risk [41] , suggesting that not just the magnitude and affinity, but also the isotype of SARS-CoV-2 Ig may play a role in PASC.

How the persistence of SARS-CoV-2 antigen may mechanistically lead to individual postacute symptoms remains unclear, but a number of investigations into the immunological basis for PASC and isolated case studies have identified dysregulation of CD8 + T cell responses as a correlate of risk [42] [43] [44] . Immune signatures of BAL (bronchoalveolar lavage) fluid in older individuals with PASC at 60-90 days post-infection revealed a persistent increase in the frequency of CD69 + CD103 -CD8 + T RM cells, as well as inflammatory signatures among myeloid cells [44] . Following peptide stimulation, the CD69 + CD103 -CD8 + T cells in convalescent subjects were polyfunctional for cytotoxic cytokine production, and expressed granzyme K, which can promote fibroblast activation. In contrast, Peluso et al. [43] observed PASC patients 4 months out from infection to have a reduced frequency of degranulationprone CD107a + CD8 + T cells in the peripheral blood. Moreover, the frequency of nucleocapsidspecific IFNγ-secreting CD8 + T cells declined more quickly in individuals with PASC in this study. It is possible that the preferential antigen-specific activation of pathogenic CD103 -CD8 + T cells leads to cytotoxic lung tissue damage and pathology, or that cytotoxic CD8 + T cell J o u r n a l P r e -p r o o f exhaustion limits the capacity for complete viral or viral antigen clearance. Importantly, these possibilities are not mutually exclusive.

Stimulation of B cells via antigen receptor binding is known to lead to the expansion of atypical memory B cells (atMBCs) during chronic or repeated intracellular infection or vaccination [45] . atMBCs are also associated with the production of autoantibodies in several autoimmune diseases, and were observed to be expanded in the peripheral blood of individuals with PASC prior to the onset of symptoms [13] . Cheon and colleagues [44] also observed elevated frequencies of activated resident memory-like CD27 + CD69 + B cells in the BAL fluid of aged convalescent subjects, and several studies have shown or suggested a potential relationship between peripheral autoantibody levels and PASC [46, 47] . Further investigation will be required to determine whether atMBCs and circulating autoantibodies detected in PASC patients contribute to symptoms, or are a consequence of PASC itself.

Despite the abundance of epidemiological information about PASC, numerous critical questions remain about the role of the immune system in PASC risk, resolution, and severity. It has become clear that considerable heterogeneity exists in the presentation -and likely also the origins -of specific PASC. As has been suggested for acute SARS-CoV-2 disease, the kinetics of the immune response and the interaction of polarized subsets of immune cells are likely to be the link between identified PASC risk factors and clinical outcomes. As observed by Su et al. [13] , it is possible that early or inappropriately-skewed acute T and B cell response could cause local tissue damage-related PASC. Alternatively, delayed activation or exhaustion of the adaptive immune response to SARS-CoV-2 infection could result in un-tempered J o u r n a l P r e -p r o o f inflammation and secondary viral/antigen dissemination and inflammation at distal sites.

Indeed, respiratory and GI PASC were proposed to be driven by divergent early transcriptional programs [13] , and although these programs may have preexisting pathological origins, differences in the kinetics of recruitment could also account for these disparities.

Another outstanding question is the nature and mechanistic underpinnings of severe post-acute symptoms observed in some younger individuals. One sub-group of PASC symptoms, Multisystem Inflammatory Syndrome in Children (MIS-C), is a rare acute shock-like syndrome affecting pediatric populations during SARS-CoV-2 convalescence. Recent analyses have identified marked activation of vascular patrolling CX3CR1 + CD8 + T cells [48] and dysregulated IFNγ responses [49] during MIS-C. It will be important to determine whether some cases of PASC in adults follow a parallel mechanism of development, considering the similarities between the infectious context and potential immunological basis for these conditions. Additionally, it will be intriguing to explore whether pre-existing cross-reactive This work provides support for SARS-CoV-2 as a catalyst for non-specific immune activation and increased susceptibility to opportunistic infection. 

High-dimensional characterization of post-acute sequelae of COVID-19

This article provided extensive characterization of symptoms and comorbidities associated with SARS-CoV-2 post-acute illness

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Attributes and predictors of long COVID

This study describes the results of a comprehensive data analysis using medical records from the Veterans Affairs healthcare system. A correlation between disease severity and the risk of PASC was identified after adjusting for confounders

Characteristics of Adult Outpatients and Inpatients with COVID-19 -11 Academic Medical Centers

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

This work identified elevated serum C-reactive protein in individuals with PASC

Markers of Immune Activation and Inflammation in Individuals with Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Analyses of Post-COVID-19 Complications and Neurological Manifestations

Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

This study used plasma and single cell multi-omic approaches to provide the most comprehensive analysis to date of predictors of PASC risk from medical records and biological specimens. The authors identified pre-existing co-morbidities, SARS-CoV-2 RNAemia, EBV viremia, and autoantibodies as risk factors, and found that immunological polarization was divergent early post-infection and associated with specific PASC symptoms

Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

This study examined the peripheral blood immune profile of SARS-CoV-2 convalescents and age and sex-matched controls 8 months following infection, finding persistent activation of innate immune cells, and elevated inflammatory and antiviral markers

Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection

Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation

This study suggests that persistent immune activation in the post-acute phase causes endothelial dysfunction

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms

Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. Front Immunol 2021, 12:682120. human body and brain

This pre-print describes the results of autopsies of individuals who died following infection with SARS-CoV-2. The authors describe the location and quantity of SARS-CoV-2 culturable virus, RNA, and sub-genomic RNA in multiple organs and tissues and from subjects at varying time points post-infection

Evolution of antibody immunity to SARS-CoV-2

This study provides evidence of SARS-CoV-2 antigen persistence based on the apparent evolution of memory B cell profiles

Reversetranscribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues

No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing

No evidence of SARS-CoV-2 reverse transcription and integration as the origin of chimeric transcripts in patient tissues

SARS-CoV-2-Host Chimeric RNA-Sequencing Reads Do Not Necessarily Arise from Virus Integration Into the Host DNA

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

This work found that risk of long-term sequelae was reduced by 49% in vaccinated individuals

Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses

Waickman AT: Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity

Germinal center enhancement by extended antigen availability

Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells

This work assessed numerous tissues from organ donations after SARS-CoV-2 infection, demonstrating that antigen-specific memory B and T cells are present in the bone marrow, spleen, lung, and lymph nodes for up to 6 months after infection

Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome

SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual with an Impaired CD8+ T Cell Response

Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms

High dimensional flow cytometry and single cell RNA sequencing provide insights into potential immunological drivers of post-acute lung sequelae

Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans

Evidence of Persisting Autoreactivity in Post-Acute Sequelae of SARS-CoV-2 Infection. MedRxiv pre-print: Rheumatology

Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study

Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19

This study of subjects with MIS-C shows that vascular patrolling CX3CR1+ CD8+ T cells are distinctly activated during MIS-C

Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

We gratefully acknowledge Drs. J. Wilmore and A. Wegman for their helpful comments.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Graphical abstract created with BioRender.com.

K.L.N. and A.T.W. wrote and edited the manuscript.

The authors declare no competing interests.